Lisa H. Butterfield

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Immunology and Microbiology · Life Sciences

67h-index16.7kcitations499works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(283), Cancer Immunotherapy and Biomarkers(177), CAR-T cell therapy research(139), Immune Cell Function and Interaction(57), vaccines and immunoinformatics approaches(57)

Publications492 total

Serum Arginase−1 is a predictive biomarker for melanoma patients and a surrogate indicator of systemic myeloid cell fitness
UNC Libraries·2025Open Access
Serum Arginase−1 is a predictive biomarker for melanoma patients and a surrogate indicator of systemic myeloid cell fitness
OncoImmunology·2025Open Access
Supplementary Figure 1 from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
2025Open Access
Supplementary Figure 3 from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
2025Open Access
Supplementary Figure Legends from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
2025Open Access
Supplementary Figure 5 from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
2025Open Access
Supplementary Table 1 from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
2025Open Access
Supplementary Figure 7 from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
2025Open Access
Supplementary Figure 4 from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
2025Open Access
Supplementary Figure 2 from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
2025Open Access
Supplementary Figure 6 from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
2025Open Access
Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
2025Open Access
Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
2025Open Access
Supplementary Data from Polyunsaturated Fatty Acid–Bound α-Fetoprotein Promotes Immune Suppression by Altering Human Dendritic Cell Metabolism
2025Open Access
Advances in the development of personalized neoantigen therapies
The Journal of Experimental Medicine·2025
Supplementary Figure S2 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
2025Open Access
Supplementary Figure S4 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
2025Open Access
Supplementary Table S2 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
2025Open Access
Supplementary Figure S3 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
2025Open Access
Supplementary Figure S6 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
2025Open Access
page 1 of 25Next →

Frequent Co-authors

James S. Economou(15), Antoni Ribas(14), John A. Glaspy(12), Theresa L. Whiteside(11), John M. Kirkwood(10), William H. McBride(10), Vivian B. Dissette(10), Paweł Kaliński(6), Douglas M. Potter(6), Ahmad A. Tarhini(6), Charles Lee(5), Sylvia Janetzki(5), Hideho Okada(4), Giuseppe Masucci(4), Charles M. Vollmer(4), Wilson S. Meng(4), Sjoerd H. van der Burg(4), Ronald L. Hamilton(3), Ian F. Pollack(3), Cindy Sander(3)